Cargando…

ZIKV Envelope Domain-Specific Antibodies: Production, Purification and Characterization

Infection with Zika virus (ZIKV) came first to public attention after it was found to be associated with congenital microcephaly during the outbreak in Brazil (2015–2016). Diagnosis of ZIKV suffers from extensive cross-reactivity with other Flaviviruses, which are circulating in many ZIKV epidemic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Akhras, Sami, Herrlein, Marie-Luise, Elgner, Fabian, Holzhauser, Thomas, Hildt, Eberhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723789/
https://www.ncbi.nlm.nih.gov/pubmed/31412626
http://dx.doi.org/10.3390/v11080748
_version_ 1783448851944833024
author Akhras, Sami
Herrlein, Marie-Luise
Elgner, Fabian
Holzhauser, Thomas
Hildt, Eberhard
author_facet Akhras, Sami
Herrlein, Marie-Luise
Elgner, Fabian
Holzhauser, Thomas
Hildt, Eberhard
author_sort Akhras, Sami
collection PubMed
description Infection with Zika virus (ZIKV) came first to public attention after it was found to be associated with congenital microcephaly during the outbreak in Brazil (2015–2016). Diagnosis of ZIKV suffers from extensive cross-reactivity with other Flaviviruses, which are circulating in many ZIKV epidemic areas. Due to the fatal outcome of ZIKV infection during pregnancy, detailed knowledge about neutralizing and non-neutralizing epitopes is crucial for the development of robust detection systems of protective antibodies. Therefore, additional information about ZIKV immunogenicity and antibody response is required. In this project, we report the production, purification and characterization of six different polyclonal antibodies against ZIKV envelope (E) protein. The produced antibodies bind to isolated ZIKV E protein as well as to the surface of ZIKV particles, interestingly without being potently neutralizing. Surface plasmon resonance measurement showed that these antibodies bind with high affinity to ZIKV E protein. Epitope mapping revealed that the epitopes are distributed among the three ZIKV E domains with seven binding sites. These identified binding sites overlap only partially with the previously described epitopes recognized by neutralizing antibodies, which is in accordance with their lack of potent neutralizing activity. Additionally, these antibodies showed neither cross-reactivity nor potent neutralizing activity against West Nile virus, a related flavivirus. The gained set of data helps to extend our understanding about the distribution of neutralizing and non-/weak-neutralizing epitopes in ZIKV E protein, and provides a rationale for ZIKV vaccine design and development of robust detection assays for neutralizing antibodies.
format Online
Article
Text
id pubmed-6723789
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67237892019-09-10 ZIKV Envelope Domain-Specific Antibodies: Production, Purification and Characterization Akhras, Sami Herrlein, Marie-Luise Elgner, Fabian Holzhauser, Thomas Hildt, Eberhard Viruses Article Infection with Zika virus (ZIKV) came first to public attention after it was found to be associated with congenital microcephaly during the outbreak in Brazil (2015–2016). Diagnosis of ZIKV suffers from extensive cross-reactivity with other Flaviviruses, which are circulating in many ZIKV epidemic areas. Due to the fatal outcome of ZIKV infection during pregnancy, detailed knowledge about neutralizing and non-neutralizing epitopes is crucial for the development of robust detection systems of protective antibodies. Therefore, additional information about ZIKV immunogenicity and antibody response is required. In this project, we report the production, purification and characterization of six different polyclonal antibodies against ZIKV envelope (E) protein. The produced antibodies bind to isolated ZIKV E protein as well as to the surface of ZIKV particles, interestingly without being potently neutralizing. Surface plasmon resonance measurement showed that these antibodies bind with high affinity to ZIKV E protein. Epitope mapping revealed that the epitopes are distributed among the three ZIKV E domains with seven binding sites. These identified binding sites overlap only partially with the previously described epitopes recognized by neutralizing antibodies, which is in accordance with their lack of potent neutralizing activity. Additionally, these antibodies showed neither cross-reactivity nor potent neutralizing activity against West Nile virus, a related flavivirus. The gained set of data helps to extend our understanding about the distribution of neutralizing and non-/weak-neutralizing epitopes in ZIKV E protein, and provides a rationale for ZIKV vaccine design and development of robust detection assays for neutralizing antibodies. MDPI 2019-08-13 /pmc/articles/PMC6723789/ /pubmed/31412626 http://dx.doi.org/10.3390/v11080748 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Akhras, Sami
Herrlein, Marie-Luise
Elgner, Fabian
Holzhauser, Thomas
Hildt, Eberhard
ZIKV Envelope Domain-Specific Antibodies: Production, Purification and Characterization
title ZIKV Envelope Domain-Specific Antibodies: Production, Purification and Characterization
title_full ZIKV Envelope Domain-Specific Antibodies: Production, Purification and Characterization
title_fullStr ZIKV Envelope Domain-Specific Antibodies: Production, Purification and Characterization
title_full_unstemmed ZIKV Envelope Domain-Specific Antibodies: Production, Purification and Characterization
title_short ZIKV Envelope Domain-Specific Antibodies: Production, Purification and Characterization
title_sort zikv envelope domain-specific antibodies: production, purification and characterization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723789/
https://www.ncbi.nlm.nih.gov/pubmed/31412626
http://dx.doi.org/10.3390/v11080748
work_keys_str_mv AT akhrassami zikvenvelopedomainspecificantibodiesproductionpurificationandcharacterization
AT herrleinmarieluise zikvenvelopedomainspecificantibodiesproductionpurificationandcharacterization
AT elgnerfabian zikvenvelopedomainspecificantibodiesproductionpurificationandcharacterization
AT holzhauserthomas zikvenvelopedomainspecificantibodiesproductionpurificationandcharacterization
AT hildteberhard zikvenvelopedomainspecificantibodiesproductionpurificationandcharacterization